Comparison of Triglyceride-Glucose Index and Atherogenic Indices Between Patients With Lipedema and Obese Controls: A Cross-Sectional Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Triglyceride-Glucose Index (TyG):
研究概览
简要总结
Women aged 18-75 years with a clinical diagnosis of lipedema and an obese control group will be included in the study. Sociodemographic and clinical data (age, height, weight, medications, etc.) of the participants will be recorded. For laboratory evaluation, fasting blood test results obtained within the last three months (including fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides) will be used. Based on these parameters, metabolic and atherogenic risk indicators such as the Triglyceride-Glucose Index (TyG), TyG-BMI, Atherogenic Index of Plasma (AIP), Atherogenic Coefficient (AC), Castelli Risk Index I (CRI-I), and Castelli Risk Index II (CRI-II) will be calculated. No additional biochemical tests will be collected from participants; analyses will be performed using existing laboratory results.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Clinically diagnosed with lipedema
- •Obese control group with BMI ≥30 kg/m² who do not meet lipedema criteria
- •Aged between 18 and 75 years
- •Availability of fasting lipid profile and fasting glucose tests within the past 3 months
- •Provided voluntary informed consent
排除标准
- •Use of medications that routinely affect lipid or glucose metabolism: statins, fibrates, niacin, ezetimibe, high-dose omega-3 supplements, GLP-1 receptor agonists, SGLT2 inhibitors, or systemic corticosteroids (regular use within the past 3 months)
- •Presence of rheumatologic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or active malignancy
- •Neurological disorders (e.g., polyneuropathy, multiple sclerosis, history of stroke)
- •Pregnancy or lactation
- •History of lower extremity surgery or major trauma within the past 6 months
- •Received injection therapy or physical therapy for the lower extremities within the past 6 months
- •Active infection or dermatological disease affecting the lower extremities
- •History of significant venous insufficiency or acute deep vein thrombosis (DVT)
- •Alcohol or substance abuse
结局指标
主要结局
Triglyceride-Glucose Index (TyG):
时间窗: Baseline
The TyG index will be calculated as ln \[fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2\]. It serves as a surrogate marker for insulin resistance. Higher values indicate greater metabolic risk.
次要结局
- TyG-BMI(Baseline)
- Atherogenic Index of Plasma (AIP):(Baseline)
- Atherogenic Coefficient (AC):(Baseline)
- Castelli Risk Index I (CRI-I):(Baseline)
- Castelli Risk Index II (CRI-II):(Baseline)
研究者
Fatma Nur Kesiktaş
Principal Investigator
Istanbul Physical Medicine Rehabilitation Training and Research Hospital